| D010039 |
Otorhinolaryngologic Neoplasms |
A general concept for tumors or cancer of any part of the EAR; the NOSE; the THROAT; and the PHARYNX. It is used when there is no specific heading. |
Neoplasms, Otorhinolaryngologic,Neoplasms, Otorhinolaryngological,Ootorhinolaryngeal Neoplasms,Otorhinolaryngeal Cancer,Otorhinolaryngologic Neoplasm,Otorhinolaryngological Neoplasms,Cancer, Otorhinolaryngeal,Cancers, Otorhinolaryngeal,Neoplasm, Ootorhinolaryngeal,Neoplasm, Otorhinolaryngologic,Neoplasm, Otorhinolaryngological,Neoplasms, Ootorhinolaryngeal,Ootorhinolaryngeal Neoplasm,Otorhinolaryngeal Cancers,Otorhinolaryngological Neoplasm |
|
| D002457 |
Cell Extracts |
Preparations of cell constituents or subcellular materials, isolates, or substances. |
Cell Extract,Extract, Cell,Extracts, Cell |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D000276 |
Adjuvants, Immunologic |
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. |
Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants |
|